1. Australia Stocks

  2. •

    Health services

  3. •

    Medical/Nursing services
Proteomics International Laboratories Ltd.

Proteomics International Laboratories Ltd.

0.12
AUD
0.00
(0.00%)
-0.06EPS
53.14MMarket Cap
Feb 25Next Earn
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
Revenue per Share
- -
0.02
0.02
0.02
0.02
0.02
0.02
0.01
0.01
0.01
0.01
0.01
Basic EPS, GAAP
- -
-0.04
-0.03
-0.02
-0.02
-0.03
-0.02
-0.03
-0.05
-0.05
-0.05
-0.06
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Dividend per Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Book Value per Share
0.27
0.04
0.02
0.03
0.06
0.04
0.05
0.07
0.03
0.07
0.07
0.08
Tangible Book Value per Share
0.27
0.04
0.02
0.03
0.06
0.04
0.05
0.07
0.03
0.07
0.07
0.08
Basic Weighted Avg Shares
18
26
51
55
61
80
87
102
106
116
126
134
Sales/Revenue/Turnover
- -
1
1
1
1
1
1
1
1
1
1
1
Operating Margin (%)
- -
-143.98
-233.64
798.54
-199.55
-209.12
-232.87
-343.87
-464.52
-1,207.15
-1,022.79
-1,105.67
Depreciation Expense
- -
- -
- -
- -
- -
- -
- -
- -
- -
1
1
1
Net Income, GAAP
- -
-1
-1
-1
-1
-2
-2
-3
-5
-6
-6
-8
Effective Tax Rate (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Profit Margin (%)
- -
-188.89
-162.63
-99.04
-122.41
-141.7
-122.54
-218.16
-333.91
-845.71
-714.71
-844.95
Working Capital
5
2
1
2
3
3
4
7
3
7
8
12
LT Debt
- -
- -
- -
1
- -
- -
- -
- -
- -
- -
- -
- -
Total Equity
5
2
1
2
5
3
4
8
3
8
9
13
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Common Equity (%)
- -
-34.07
-102.32
-76.33
-45.82
-54.3
-46.98
-47.47
-90.39
-104.91
-71.67
-71.87

Capital Structure

AUD

•

in mil. unless spec.
No data availableFinancial data will appear here once available

Working Capital

AUD

•

in mil. unless spec.
No data availableFinancial data will appear here once available

Growth Rates

AUD

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
46.28%
42.53%
40.2%
Free Cash Flow
- -
- -
- -
Net Income, GAAP
26.26%
38.52%
27.27%
Sales/Revenue/Turnover
8.1%
-3.09%
7.65%
Total Cash Common Dividend
- -
- -
- -

Semi-annual Revenue

AUD

•

in mil. unless spec.

Year

H1
H2
FY
2023
- -
- -
1
2024
- -
- -
1
2025
- -
- -
1

Semi-annual Earnings Per Share

AUD

•

in mil. unless spec.

Year

H1
H2
FY
2023
- -
- -
-0.05
2024
- -
- -
-0.05
2025
- -
- -
-0.06

Semi-annual Dividends Per Share

AUD

•

in mil. unless spec.

Year

H1
H2
FY
2023
- -
- -
- -
2024
- -
- -
- -
2025
- -
- -
- -

Company Description

Company Profile APIChatGPT
CEO
David N. Morris
Full Time Employees
161
Sector
Health services
Industry
Medical/Nursing services
Address
Harry Perkins Institute of Medical Research Perth WA Australia 6009
IPO Date
Apr 16, 2015
Website
proteomics.com.au
Similar Companies
Hims & Hers Health, Inc. (NYSE:HIMS)
Ginkgo Bioworks Holdings, Inc. (NYSE:DNA)
Mobile-health Network Solutions (NASDAQ:MNDR)
Dr. Lal PathLabs Limited (NSE:LALPATHLAB)
Tenon Medical, Inc. (NASDAQ:TNON)
Teladoc Health, Inc. (NYSE:TDOC)
Business
Proteomics International Laboratories Ltd (ASX:PIQ) is an Australia-based medical technology company specializing in proteomics, the large-scale study of protein structure and function, with a focus on predictive diagnostics for chronic diseases and bioanalytical services. Founded in 2001 and headquartered at the Harry Perkins Institute of Medical Research in Nedlands, Perth, Western Australia, the company develops and commercializes precision diagnostic tests including PromarkerD, a blood-based predictive test for diabetic kidney disease in type 2 diabetes patients; PromarkerEndo for endometriosis; PromarkerEso, a non-invasive test for esophageal cancer; and OxiDx; alongside specialist analytical services such as bioanalytical testing, protein and peptide analysis, biosimilar characterization, biomarker discovery and validation, pharmacokinetic testing, and contract research for clinical trials. It operates trading entities in the European Union, India, and the United States, serving pharmaceutical, veterinary, and agricultural sectors through its ISO 17025-accredited laboratory, the first worldwide for proteomics services since 2009, and holds NATA accreditation for clinical pathology under ISO 15189:2022. Recent developments include expansion of its Perth laboratory to support global precision diagnostics leadership; receipt of a A$0.5 million Western Australia Innovation Grant for PromarkerEndo commercialization; achievement of NATA accreditation for the Perth lab; U.S. AMA reimbursement code approval for PromarkerD; expanded collaboration for endometriosis diagnostics advancement; clinical validation demonstrating high accuracy for the PromarkerEso esophageal cancer test; and appointment of Vicki Robinson as a new director.